For moderate to severe pain.
Allergan announced positive 3-month topline results from the second pivotal clinical trial of bimatoprost SR , a first-in-class sustained-release, biodegradable...
Allergan announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant...
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
This study will evaluate the intraocular pressure-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication.
Takeda Pharmaceutical Company Limited and its partner, Zinfandel Pharmaceuticals, Inc. announced that the global Phase III TOMMORROW trial has been...
Allergan plc, has announced that the FDA has accepted the company's New Drug Application (NDA) for Bimatoprost Sustained-Release (SR). Bimatoprost...